LivaNova Appoints New President of Cardiopulmonary Division
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2026
0mins
Source: Newsfilter
- Leadership Transition: LivaNova PLC announced that Stefano Folli will succeed Franco Poletti as President of Cardiopulmonary effective June 1, ensuring a smooth leadership transition that is expected to enhance the company's strategic execution in the cardiopulmonary medical technology sector.
- Business Scale: Folli will oversee a nearly $800 million cardiopulmonary business, including the Essenz™ Perfusion System, and is anticipated to drive growth and innovation through his extensive industry experience.
- Experience Background: Folli's previous role as Global President of Ambulatory Monitoring & Diagnostics at Philips involved successful integration of acquisitions and strengthening market leadership, showcasing his deep expertise and leadership capabilities that will bring new perspectives and strategies to LivaNova.
- Strategic Vision: Folli expressed his commitment to collaborating with the global team to enhance execution and innovation, aiming to improve outcomes for patients and clinicians, which underscores LivaNova's long-term dedication to the medical technology field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LIVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LIVN
Wall Street analysts forecast LIVN stock price to fall
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 73.040
Low
64.00
Averages
72.50
High
85.00
Current: 73.040
Low
64.00
Averages
72.50
High
85.00
About LIVN
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LivaNova Appoints New President of Cardiopulmonary Division
- Leadership Transition: LivaNova PLC announced that Stefano Folli will succeed Franco Poletti as President of Cardiopulmonary effective June 1, ensuring a smooth leadership transition that is expected to enhance the company's strategic execution in the cardiopulmonary medical technology sector.
- Business Scale: Folli will oversee a nearly $800 million cardiopulmonary business, including the Essenz™ Perfusion System, and is anticipated to drive growth and innovation through his extensive industry experience.
- Experience Background: Folli's previous role as Global President of Ambulatory Monitoring & Diagnostics at Philips involved successful integration of acquisitions and strengthening market leadership, showcasing his deep expertise and leadership capabilities that will bring new perspectives and strategies to LivaNova.
- Strategic Vision: Folli expressed his commitment to collaborating with the global team to enhance execution and innovation, aiming to improve outcomes for patients and clinicians, which underscores LivaNova's long-term dedication to the medical technology field.
See More
LivaNova (LIVN) Q1 2025 Earnings Transcript
See More
LIVANOVA: BARCLAYS INCREASES TARGET PRICE TO $76, UP FROM $73
- Company Update: Livanova has raised its target price to $76 from $73.
- Market Reaction: The adjustment reflects positive market sentiment towards Livanova's performance and future prospects.
See More
LivaNova Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: LivaNova achieved an 11% revenue growth in Q1 2026, reaching $362 million, demonstrating strong performance in its cardiopulmonary and epilepsy segments, which enhances the company's competitive position in the medical device market.
- Optimistic Market Outlook: The company now expects cardiopulmonary revenue growth for 2026 to rise to 8.5%-9.5% and epilepsy growth to 6%-7%, reflecting management's confidence in future market demand.
- FDA Approval of New Device: LivaNova received FDA premarket approval for the aura6000 system, the first hypoglossal nerve stimulation device approved without complete consent, marking a strategic entry into the obstructive sleep apnea market.
- Cash Flow and Investment: The adjusted free cash flow for Q1 was $4 million, while capital expenditures were $14 million, primarily driven by cardiopulmonary capacity expansion and next-generation oxygenator manufacturing upgrades, indicating the company's commitment to ongoing investments for future growth.
See More
LivaNova Reports Q1 2026 Financial Results with Raised Guidance
- Significant Revenue Growth: LivaNova reported Q1 2026 revenue of $362.3 million, reflecting a 14.3% increase year-over-year and an 11.1% rise on a constant-currency basis, showcasing strong performance in its Cardiopulmonary and Epilepsy segments, thereby enhancing market competitiveness.
- Upgraded Earnings Guidance: The company raised its full-year 2026 revenue growth forecast to 7.0%-8.0% and adjusted diluted earnings per share guidance to $4.20-$4.30, indicating strong operational execution and market confidence.
- FDA Approval for New Device: LivaNova received FDA premarket approval for its aura6000 System, the first hypoglossal nerve stimulation device approved without contraindications for complete concentric collapse, marking a strategic breakthrough in the obstructive sleep apnea market.
- Clinical Trial Results Published: The company published full 12-month results from the OSPREY randomized controlled trial in the Annals of Internal Medicine, demonstrating significant clinical responses and sustained improvements, further solidifying its market position.
See More
LivaNova Releases OSPREY Trial Data on pHGNS for OSA
- Clinically Significant Improvements: The OSPREY trial demonstrated that pHGNS treatment significantly reduced the apnea-hypopnea index (AHI) in moderate to severe obstructive sleep apnea (OSA) patients, with the median AHI dropping from 34.3 to 11.6 after 7 months, indicating substantial clinical relevance in enhancing patient sleep quality.
- Diverse Patient Population: The trial included 104 participants with varied demographics and OSA severity, ensuring the findings are broadly applicable, particularly for patients intolerant to positive airway pressure (PAP) therapy, showcasing pHGNS as a viable alternative treatment option.
- Safety and Efficacy: No serious adverse events were reported, with most treatment-emergent adverse events being mild or moderate, underscoring the safety of pHGNS in clinical applications and enhancing its competitive position in the market.
- Future Market Outlook: LivaNova plans to independently commercialize its next-generation OSA device by 2027, leveraging FDA approval and strong clinical results to potentially provide effective treatment options for the approximately 1 billion undiagnosed OSA patients worldwide.
See More
LivaNova Appoints New President of Cardiopulmonary Division
- Leadership Transition: LivaNova PLC announced that Stefano Folli will succeed Franco Poletti as President of Cardiopulmonary effective June 1, ensuring a smooth leadership transition that is expected to enhance the company's strategic execution in the cardiopulmonary medical technology sector.
- Business Scale: Folli will oversee a nearly $800 million cardiopulmonary business, including the Essenz™ Perfusion System, and is anticipated to drive growth and innovation through his extensive industry experience.
- Experience Background: Folli's previous role as Global President of Ambulatory Monitoring & Diagnostics at Philips involved successful integration of acquisitions and strengthening market leadership, showcasing his deep expertise and leadership capabilities that will bring new perspectives and strategies to LivaNova.
- Strategic Vision: Folli expressed his commitment to collaborating with the global team to enhance execution and innovation, aiming to improve outcomes for patients and clinicians, which underscores LivaNova's long-term dedication to the medical technology field.
See More
LivaNova (LIVN) Q1 2025 Earnings Transcript
See More
LIVANOVA: BARCLAYS INCREASES TARGET PRICE TO $76, UP FROM $73
- Company Update: Livanova has raised its target price to $76 from $73.
- Market Reaction: The adjustment reflects positive market sentiment towards Livanova's performance and future prospects.
See More
LivaNova Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: LivaNova achieved an 11% revenue growth in Q1 2026, reaching $362 million, demonstrating strong performance in its cardiopulmonary and epilepsy segments, which enhances the company's competitive position in the medical device market.
- Optimistic Market Outlook: The company now expects cardiopulmonary revenue growth for 2026 to rise to 8.5%-9.5% and epilepsy growth to 6%-7%, reflecting management's confidence in future market demand.
- FDA Approval of New Device: LivaNova received FDA premarket approval for the aura6000 system, the first hypoglossal nerve stimulation device approved without complete consent, marking a strategic entry into the obstructive sleep apnea market.
- Cash Flow and Investment: The adjusted free cash flow for Q1 was $4 million, while capital expenditures were $14 million, primarily driven by cardiopulmonary capacity expansion and next-generation oxygenator manufacturing upgrades, indicating the company's commitment to ongoing investments for future growth.
See More
LivaNova Reports Q1 2026 Financial Results with Raised Guidance
- Significant Revenue Growth: LivaNova reported Q1 2026 revenue of $362.3 million, reflecting a 14.3% increase year-over-year and an 11.1% rise on a constant-currency basis, showcasing strong performance in its Cardiopulmonary and Epilepsy segments, thereby enhancing market competitiveness.
- Upgraded Earnings Guidance: The company raised its full-year 2026 revenue growth forecast to 7.0%-8.0% and adjusted diluted earnings per share guidance to $4.20-$4.30, indicating strong operational execution and market confidence.
- FDA Approval for New Device: LivaNova received FDA premarket approval for its aura6000 System, the first hypoglossal nerve stimulation device approved without contraindications for complete concentric collapse, marking a strategic breakthrough in the obstructive sleep apnea market.
- Clinical Trial Results Published: The company published full 12-month results from the OSPREY randomized controlled trial in the Annals of Internal Medicine, demonstrating significant clinical responses and sustained improvements, further solidifying its market position.
See More
LivaNova Releases OSPREY Trial Data on pHGNS for OSA
- Clinically Significant Improvements: The OSPREY trial demonstrated that pHGNS treatment significantly reduced the apnea-hypopnea index (AHI) in moderate to severe obstructive sleep apnea (OSA) patients, with the median AHI dropping from 34.3 to 11.6 after 7 months, indicating substantial clinical relevance in enhancing patient sleep quality.
- Diverse Patient Population: The trial included 104 participants with varied demographics and OSA severity, ensuring the findings are broadly applicable, particularly for patients intolerant to positive airway pressure (PAP) therapy, showcasing pHGNS as a viable alternative treatment option.
- Safety and Efficacy: No serious adverse events were reported, with most treatment-emergent adverse events being mild or moderate, underscoring the safety of pHGNS in clinical applications and enhancing its competitive position in the market.
- Future Market Outlook: LivaNova plans to independently commercialize its next-generation OSA device by 2027, leveraging FDA approval and strong clinical results to potentially provide effective treatment options for the approximately 1 billion undiagnosed OSA patients worldwide.
See More
